Kevin Kelly, MD

Dr. Kelly is a hematologist with clinical expertise in phase I investigational therapeutics and hematological malignancies, including lymphoma and multiple myeloma. His research focuses on understanding the mechanisms of resistance to chemotherapy in hematological malignancies and the use of novel agents to overcome this resistance, and he has published extensively in peer-reviewed journals. Through collaborations with a large team of scientists, he has translated preclinical discoveries into novel clinical trials including an investigator-initiated study of the phosphodiesterase 4B inhibitor, roflumilast, in B cell lymphoproliferative disorders.

Dr. Kelly earned his medical degree and PhD from University College Cork. He then went on to complete an Advanced Drug Development Clinical Fellowship at The University of Texas Health Science Center.

• National Cancer Institute: Cancer Clinical Investigator Team Leadership Award, 2016
• EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Travel Award, 2011
• ASCO/AACR Workshop on Methods in Clinical Cancer Research: Travel Award, 2009